GE HealthCare Technologies (GEHC) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 7, 2026, with record date March 9, 2026; 456,290,143 shares outstanding and entitled to vote.

• Key proposals: election of 8 directors, advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor for 2026.

• Company reported $20.6 billion in revenue for 2025, with 4.8% year-over-year growth and $2.1 billion net income.

• Strategy focuses on precision care, connected care pathways, growth acceleration, and business optimization.

Voting matters and shareholder proposals

• Board recommends voting FOR all 8 director nominees, FOR the say-on-pay proposal, and FOR auditor ratification.

• Shareholders may submit proposals for the 2027 meeting by November 19, 2026, and director nominations via proxy access between October 20 and November 19, 2026.

• Proxy access allows groups holding at least 3% of shares for 3 years to nominate directors.

Board of directors and corporate governance

• Board will have 8 directors post-meeting, 7 of whom are independent; diversity in gender and ethnicity.

• Annual election of all directors by majority vote; no supermajority provisions or poison pill.

• Board committees: Audit, Compensation, and Governance, all chaired by independent directors.

• Lead director role provides additional oversight and stockholder communication channel.

• Board and committee self-evaluations conducted annually; 15-year term limit for directors (except CEO).